Reuters logo
BRIEF-SCYNEXIS says achieves new development milestones for SCY-078
December 13, 2016 / 1:23 PM / a year ago

BRIEF-SCYNEXIS says achieves new development milestones for SCY-078

Dec 13 (Reuters) - SCYNEXIS Inc

* Pending discussions with FDA, plan to test in upcoming clinical trials of SCY-078

* Scynexis achieves new development milestones reinforcing versatility of SCY-078 in treating serious fungal infections

* SCY-078 toxicology program was expanded to include three-month oral dose studies in two species Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below